Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) saw a large growth in short interest in July. As of July 31st, there was short interest totaling 9,516 shares, a growth of ∞ from the July 15th total of 0 shares. Based on an average daily trading volume, of 95,837,372 shares, the days-to-cover ratio is currently 0.0 days.
Regen BioPharma Stock Performance
Regen BioPharma has a fifty-two week low of $0.00 and a fifty-two week high of $0.05.
About Regen BioPharma
Regen BioPharma, Inc is a development‐stage biotechnology company focused on advancing regenerative medicine and immunotherapy products through stem cell science. The company’s research efforts center on identifying and developing novel therapeutic candidates that harness the regenerative potential of adult and embryonic stem cells, with an emphasis on cancer, infectious and autoimmune diseases.
Its primary activities include the discovery and preclinical validation of stem cell‐derived receptors and peptides, the development of immuno‐oncology assets, and the filing of investigational new drug (IND) applications to support first‐in‐human studies.
See Also
- Five stocks we like better than Regen BioPharma
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Regen BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regen BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
